Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein

Journal of Neurochemistry

Volumn 131, Issue 6, 2014, Pages 859-867

  Rutherford, Nicola J ^a   Moore, Brenda D ^a   Golde, Todd E ^a   Giasson, Benoit I ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Parkinson's disease; protein aggregation; SNCA mutation; synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; PROTEIN AGGREGATE;

ARTICLE; ATOMIC FORCE MICROSCOPY; CELL STRESS; CELL VIABILITY; CONTROLLED STUDY; ELECTRON MICROSCOPY; FLUOROMETRY; G51D GENE; GENE MUTATION; GENETIC ASSOCIATION; H50Q GENE; INTRACELLULAR MEMBRANE; MUTATIONAL ANALYSIS; PATHOGENESIS; POLYMERIZATION; PROTEIN AGGREGATION; PROTEIN STRUCTURE; SEDIMENTATION; UPREGULATION; CELL CULTURE; GENETICS; HUMAN; METABOLISM; MUTATION; PARKINSON DISEASE;

ALPHA-SYNUCLEIN; AMYLOID; CELLS, CULTURED; HUMANS; MUTATION; PARKINSON DISEASE; PROTEIN AGGREGATES;

EID: 84918816540     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12806     Document Type: Article

References (47)

1. Appel-Cresswell S., Vilarino-Guell C., Encarnacion M., et al,. (2013) Alpha-synuclein p. H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord. 28, 811-813.
2. Auluck P. K., Caraveo G., and, Lindquist S., (2010) α-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu. Rev. Cell Dev. Biol. 26, 211-233.
3. Banerjee R., Starkov A. A., Beal M. F., and, Thomas B., (2009) Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim. Biophys. Acta 1792, 651-663.
4. Burré J., Sharma M., Tsetsenis T., Buchman V., Etherton M. R., and, Südhof T. C., (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329, 1663-1667.
5. Chartier-Harlin M. C., Kachergus J., Roumier C., et al,. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169.
6. Choi W., Zibaee S., Jakes R., Serpell L. C., Davletov B., Crowther R. A., and, Goedert M., (2004) Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett. 576, 363-368.
7. Conway K. A., Harper J. D., and, Lansbury P. T., (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318-1320.
8. Conway K. A., Lee S. J., Rochet J. C., Ding T. T., Williamson R. E., and, Lansbury P. T., Jr, (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA 97, 571-576.
9. Cookson M. R., (2005) The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 74, 29-52.
10. Crystal A. S., Giasson B. I., Crowe A., Kung M. P., Zhuang Z. P., Trojanowski J. Q., and, Lee V. M., (2003) A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. J. Neurochem. 86, 1359-1368.
11. Duda J. E., Giasson B. I., Mabon M. E., Miller D. C., Golbe L. I., Lee V. M., and, Trojanowski J. Q., (2002) Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol. 104, 7-11.
12. Fantini J., and, Yahi N., (2013) The driving force of alpha-synuclein insertion and amyloid channel formation in the plasma membrane of neural cells: key role of ganglioside- and cholesterol-binding domains. Adv. Exp. Med. Biol. 991, 15-26.
13. Fredenburg R. A., Rospigliosi C., Meray R. K., Kessler J. C., Lashuel H. A., Eliezer D., and, Lansbury P. T., Jr, (2007) The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry 46, 7107-7118.
14. Ghosh D., Mondal M., Mohite G. M., Singh P. K., Ranjan P., Anoop A., Ghosh S., Jha N. N., Kumar A., and, Maji S. K., (2013) The Parkinson's disease-associated H50Q mutation accelerates α-Synuclein aggregation in vitro. Biochemistry 52, 6925-6927.
15. Giasson B. I., Uryu K., Trojanowski J. Q., and, Lee V. M., (1999) Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 7619-7622.
16. Giasson B. I., Jakes R., Goedert M., Duda J. E., Leight S., Trojanowski J. Q., and, Lee V. M., (2000) A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J. Neurosci. Res. 59, 528-533.
17. Giasson B. I., Murray I. V., Trojanowski J. Q., and, Lee V. M., (2001) A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 276, 2380-2386.
18. Goedert M., (2001) Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492-501.
19. Greenbaum E. A., Graves C. L., Mishizen-Eberz A. J., Lupoli M. A., Lynch D. R., Englander S. W., Axelsen P. H., and, Giasson B. I., (2005) The E46K mutation in alpha-synuclein increases amyloid fibril formation. J. Biol. Chem. 280, 7800-7807.
20. Kiely A. P., Asi Y. T., Kara E., et al,. (2013) α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol. 125, 753-769.
21. Kotzbauer P. T., Giasson B. I., Kravitz A. V., Golbe L. I., Mark M. H., Trojanowski J. Q., and, Lee V. M., (2004) Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Exp. Neurol. 187, 279-288.
22. Krüger R., Kuhn W., Müller T., Woitalla D., Graeber M., Kösel S., Przuntek H., Epplen J. T., Schöls L., and, Riess O., (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108.
23. Lashuel H. A., Overk C. R., Oueslati A., and, Masliah E., (2013) The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38-48.
24. Lesage S., Anheim M., Letournel F., et al,.; French Parkinson's Disease Genetics Study Group (2013) G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 73, 459-471.
25. Li J., Uversky V. N., and, Fink A. L., (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 40, 11604-11613.
26. Luk K. C., Song C., O'Brien P., Stieber A., Branch J. R., Brunden K. R., Trojanowski J. Q., and, Lee V. M., (2009) Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl Acad. Sci. USA 106, 20051-20056.
27. Luk K. C., Kehm V. M., Zhang B., O'Brien P., Trojanowski J. Q., and, Lee V. M., (2012a) Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J. Exp. Med. 209, 975-986.
28. Luk K. C., Kehm V., Carroll J., Zhang B., O'Brien P., Trojanowski J. Q., and, Lee V. M., (2012b) Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949-953.
29. Mizutani T., Inose T., Nakajima S., Kakimi S., Uchigata M., Ikeda K., Gambetti P., and, Takasu T., (1998) Familial parkinsonism and dementia with ballooned neurons, argyrophilic neuronal inclusions, atypical neurofibrillary tangles, tau-negative astrocytic fibrillary tangles, and Lewy bodies. Acta Neuropathol. 95, 15-27.
30. Moore D. J., West A. B., Dawson V. L., and, Dawson T. M., (2005) Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28, 57-87.
31. Narhi L., Wood S. J., Steavenson S., et al,. (1999) Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 274, 9843-9846.
32. Nonaka T., Watanabe S. T., Iwatsubo T., and, Hasegawa M., (2010) Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases. J. Biol. Chem. 285, 34885-34898.
33. Norris E. H., and, Giasson B. I., (2005) Role of oxidative damage in protein aggregation associated with Parkinson's disease and related disorders. Antioxid. Redox Signal. 7, 672-684.
34. Paxinou E., Chen Q., Weisse M., Giasson B. I., Norris E. H., Rueter S. M., Trojanowski J. Q., Lee V. M., and, Ischiropoulos H., (2001) Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21, 8053-8061.
35. Polymeropoulos M. H., Lavedan C., Leroy E., et al,. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
36. Proukakis C., Dudzik C. G., Brier T., MacKay D. S., Cooper J. M., Millhauser G. L., Houlden H., and, Schapira A. H., (2013) A novel α-synuclein missense mutation in Parkinson disease. Neurology 80, 1062-1064.
37. Sacino A. N., Thomas M. A., Ceballos-Diaz C., Cruz P. E., Rosario A. M., Lewis J., Giasson B. I., and, Golde T. E., (2013) Conformational templating of α-synuclein aggregates in neuronal-glial cultures. Mol. Neurodegener. 8, 17.
38. Sacino A. N., Brooks M., Thomas M. A., McKinney A. B., McGarvey N. H., Rutherford N. J., Ceballos-Diaz C., Robertson J., Golde T. E., and, Giasson B. I., (2014) Amyloidogenic α-synuclein seeds do no invariably induce rapid, widespread pathology in mice. Acta Neuropathol. 127, 645-665.
39. Singleton A. B., Farrer M., Johnson J., et al,. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841.
40. Spira P. J., Sharpe D. M., Halliday G., Cavanagh J., and, Nicholson G. A., (2001) Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann. Neurol. 49, 313-319.
41. Waxman E. A., and, Giasson B. I., (2008) Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J. Neuropathol. Exp. Neurol. 67, 402-416.
42. Waxman E. A., and, Giasson B. I., (2009) Molecular mechanisms of alpha-synuclein neurodegeneration. Biochim. Biophys. Acta 1792, 616-624.
43. Waxman E. A., and, Giasson B. I., (2010) A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation. J. Neurochem. 113, 374-388.
44. Welch K., and, Yuan J., (2003) Alpha-synuclein oligomerization: a role for lipids? Trends Neurosci. 26, 517-519.
45. Wood S. J., Wypych J., Steavenson S., Louis J. C., Citron M., and, Biere A. L., (1999) alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274, 19509-19512.
46. Yamaguchi K., Cochran E. J., Murrell J. R., Polymeropoulos M. H., Shannon K. M., Crowther R. A., Goedert M., and, Ghetti B., (2005) Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the alpha-synuclein gene. Acta Neuropathol. 110, 298-305.
47. Zarranz J. J., Alegre J., Gõmez-Esteban J. C., et al,. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173.